Oura Expands Health Radar and GLP-1 Insights to Over 30 New Global Markets in Major Preventative Care Rollout

Oura, the health intelligence platform renowned for its wearable smart rings, has announced a significant international expansion of its proactive and contextual health features, bringing advanced wellness tools to users in more than 30 new markets. Rolling out progressively over the coming weeks starting October 6, 2026, members residing across the European Union, the United Kingdom, Canada, Australia, New Zealand, Mexico, and Saudi Arabia will gain access to Oura’s suite of sophisticated physiological monitoring capabilities. This global deployment marks a major milestone in the company’s strategic shift away from passive sleep and activity tracking toward active, preventative healthcare management.

The expanded software package introduces several flagship capabilities to the Oura App for users equipped with an Oura Ring Gen3 or newer, operating on both iOS and Android devices. Among the newly available tools are Health Radar—which encompasses blood pressure signals and nighttime breathing metrics—alongside Nighttime Blood Pressure tracking, manual cuff data integration, and specialized GLP-1 Insights. By bridging the gap between continuous wearable biometrics and lifestyle management, the company aims to equip millions of new international users with the longitudinal data necessary to facilitate more informed, productive dialogues with their respective healthcare providers.

A Strategic Evolution in Preventative Health Intelligence

The deployment of these features reflects a broader industry trend toward continuous physiological monitoring as a cornerstone of preventative medicine. Modern digital health platforms are increasingly expected to move beyond simple step-counting and basic sleep scoring to offer actionable insights regarding chronic conditions, cardiovascular strain, and metabolic health. Oura’s latest international rollout addresses this demand directly by scaling tools that were previously restricted or under development, allowing a wider demographic of users to benefit from proactive health intelligence.

At the core of this expansion is Health Radar, an evolution of the company’s Symptom Radar feature launched in 2024. While Symptom Radar was primarily designed to alert users when their physiological baseline shifted suddenly—often signaling the onset of an acute illness—Health Radar takes a more comprehensive approach. Developed in collaboration with an in-house team of more than 40 medical doctors and PhDs, Health Radar continuously processes background biometric signals to detect subtle, long-term shifts in the user’s body. The overarching objective of the system is not to diagnose medical conditions, but rather to highlight patterns that may warrant lifestyle modifications, periods of rest, or formal evaluation by a clinical professional.

Cardiovascular Monitoring and Blood Pressure Signals

Cardiovascular disease remains a leading cause of mortality worldwide, yet many early indicators of heart strain remain undetectable during routine, episodic clinical check-ups. To address this diagnostic blind spot, Oura has integrated Blood Pressure Signals as a foundational element of the Health Radar architecture. This tool leverages continuous photoplethysmography (PPG) sensors within the smart ring to detect shifts and patterns that may indicate cardiovascular stress over time, providing users with early warnings before minor issues escalate into major health events.

Complementing Blood Pressure Signals are the newly introduced Nighttime BP and Cuff Input features. Sleep is widely recognized by medical professionals as the optimal state for observing cardiovascular baselines, as it effectively eliminates the physiological noise introduced by daily stressors, physical activity, and dietary stimulants such as caffeine. During a healthy night of rest, an individual’s blood pressure should naturally experience a nocturnal dip. When this dipping pattern fails to occur consistently, it can serve as an early indicator of underlying cardiovascular risks that traditional daytime office readings might miss.

By analyzing overnight PPG signals, Oura’s software can identify these crucial nocturnal trends. Furthermore, recognizing that wearables provide relative trends rather than absolute clinical measurements, the platform now allows members to log manual blood pressure cuff readings directly within the Oura App. This integration bridges real-world clinical measurements with continuous trend data, giving users a holistic view of their heart health that they can easily share with their primary care physicians.

Nighttime Breathing and Longitudinal Respiratory Tracking

In addition to cardiovascular metrics, Health Radar incorporates enhanced Nighttime Breathing monitoring. Building upon the existing nightly breathing regularity card familiar to many Oura users, this feature compiles a 30-day rolling view of sleep-related breathing patterns and disturbances. By transforming isolated night-by-night data into a broader longitudinal picture, the platform helps users identify chronic trends that may be impairing their sleep quality. The app provides clear explanations and educational guidance to help members understand when breathing fluctuations are significant enough to discuss with a healthcare specialist, reinforcing the platform’s role as a bridge to professional medical care.

Navigating the Global Rise of GLP-1 Medications

Beyond cardiovascular and respiratory health, Oura’s international expansion addresses one of the most significant pharmaceutical developments of the decade: the rapid global adoption of GLP-1 receptor agonist medications. According to World Health Organization projections, global usage of GLP-1 treatments for obesity and related metabolic conditions is expected to surpass 100 million individuals by 2030.

For patients navigating a GLP-1 treatment regimen, managing the therapy often involves a fragmented digital experience. Users typically juggle multiple applications to track weekly dosing schedules, monitor fluctuating side effects, record body weight changes, and review various biometric markers. Oura has sought to eliminate this administrative friction by introducing GLP-1 Insights, a centralized dashboard integrated directly into the Oura App.

The GLP-1 Insights feature provides a single, cohesive view of a user’s entire medication journey. Members can log their specific doses and schedules, record subjective side effects, track weight fluctuations, and correlate these inputs directly with Oura’s established biometric pillars: Sleep, Activity, Readiness, and stress. By combining pharmaceutical dosing contexts with continuous, scientifically validated physiological data, Oura has positioned itself as one of the few wearable technology providers capable of delivering a complete longitudinal record of a metabolic health journey. These structured insights are specifically designed to help patients have more productive, data-driven conversations with their prescribing physicians, optimizing both adherence and overall wellbeing.

Leadership Perspective and Corporate Vision

Reflecting on the international rollout, Dr. Ricky Bloomfield, Chief Medical Officer at Oura, emphasized the philosophical underpinning of the company’s product development strategy. “At Oura, we believe that no matter what health journey you’re on, you should be empowered to understand your unique physiology, and how it changes over time,” Dr. Bloomfield stated. He noted that Health Radar and GLP-1 Insights were engineered specifically to illuminate areas of personal health that frequently go unnoticed during standard daily routines. “Bringing these experiences to new markets means we’re giving more members around the world the tools to have informed, proactive conversations with their healthcare providers about their wellbeing, helping them to live healthier, longer.”

The expansion underscores Oura’s ongoing evolution from a niche sleep-tracking hardware manufacturer into a comprehensive health intelligence platform. Founded in Finland in 2013 and currently headquartered in San Francisco with European headquarters in Oulu, Finland, the company has built an extensive ecosystem. The Oura Ring is currently utilized by millions of members worldwide, supported by more than 1,200 commercial and research partners, including professional sports teams, major healthcare providers, and academic research institutions.

Market Availability and Regulatory Considerations

The phased deployment across the European Union, the United Kingdom, Canada, Australia, New Zealand, Mexico, and Saudi Arabia begins on October 6, 2026. The new software capabilities are accessible to all existing and new owners of the Oura Ring Gen3 or subsequent hardware iterations who utilize the mobile application on supported iOS and Android operating systems.

As Oura expands these sophisticated monitoring tools into heavily regulated international medical and wellness markets, the company has maintained clear disclaimers regarding the intended use of its software. Oura explicitly notes that Health Radar features, Nighttime Blood Pressure monitoring, cuff inputs, and GLP-1 Insights are engineered strictly for general wellness purposes. They are neither designed nor certified to diagnose, treat, cure, mitigate, monitor, or prevent any disease, illness, or medical condition, and they do not constitute professional medical advice. The platform does not prescribe pharmaceutical treatments, recommend dosage modifications, or attempt to substitute for the independent clinical judgment of a qualified healthcare provider. Instead, the company’s stated mission remains focused on delivering contextual, high-fidelity data that empowers individuals to take an active, informed role in partnership with their medical care teams.